A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Treatments: Drug: MK633; Drug: Comparator: Placebo (unspecified)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00418613

2006_509

0633-009

MK0633-009

Details and patient eligibility

About

A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).

Enrollment: 266 patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening
• Male or postmenopausal females 40 -75 years of age

Exclusion criteria

• Impaired renal function
• History of chronic liver disease or persistent liver function test (LFT) abnormalities
• History of recent cardiovascular clinical event
• Evidence of another clinically significant, active pulmonary disorder such as bronchiectasis or asthma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

266 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

MK0633

Treatment:

Drug: MK633

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Comparator: Placebo (unspecified)